Generic
Famotidine
Brand Name
Pepcid
Import ID
167
Famotidine
| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Rilpivirine (IM) Famotidine | Green: Administer standard doses | Administer standard doses | |||||
| Lenacapavir Famotidine | Green: Administer standard doses | Administer standard doses | No clinically significant effect expected |
AUC increased 28% |
40 mg daily | Not reported |
|
| Atazanavir Famotidine 798 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of atazanavir | No significant change |
20 mg BID on d 11-17 (simultaneous administration with morning atazanavir / ritonavir) | Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting. |
||
| Atazanavir Famotidine 797 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of atazanavir | Potential loss of antiretroviral efficacy |
Atazanavir AUC no significant change, Cmax no significant change, Cmin decreased 14%(compared to 300 mg atazanavir with 100 mg ritonavir daily) |
40 mg Q12H on d 11-20 | Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting. |
|
| Atazanavir Famotidine 796 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of atazanavir | Potential loss of antiretroviral efficacy |
Atazanavir Cmin decreased 31% |
40 mg daily on d 7-12 | Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting. |
|
| Atazanavir Famotidine 795 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of atazanavir | Potential loss of antiretroviral efficacy |
Atazanavir AUC decreased 41%, Cmax decreased 47%, Cmin decreased 42% |
40 mg BID on d 7-12 | Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting. |
|
| Atazanavir Famotidine 794 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of atazanavir | Potential loss of antiretroviral efficacy |
Atazanavir AUC decreased 41% |
20 mg BID on d 11-17 | Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting. |
|
| Atazanavir Famotidine 793 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of atazanavir | Potential loss of antiretroviral efficacy |
Atazanavir AUC decreased 38%, Cmax decreased 42%, Cmin decreased 40% |
40 mg Q12H | Not reported |
Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting. |
| Atazanavir Famotidine 792 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of atazanavir | Potential loss of antiretroviral efficacy |
Atazanavir AUC decreased 18%, Cmax no significant change, Cmin decreased 28% |
40 mg BID on d 11-20 | Not reported |
Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting. |
| Rilpivirine Famotidine 656 | Green: Administer standard doses | Administer standard doses | Rilpivirine Cmax increased 21% |
40 mg x 1 taken 4 hours after rilpivirine | |||
| Rilpivirine Famotidine 655 | Green: Administer standard doses | Administer standard doses | No significant change |
40 mg x 1 taken 12 hours before rilpivirine | |||
| Rilpivirine Famotidine 646 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of rilpivirine | Decreased rilpivirine effects |
Rilpivirine AUC decreased 76%; Cmax decreased 85% |
40 mg x 1 taken 2 hours before rilpivirine | Administer H2-antagonist by at least 12 hours before rilpivirine or at least 4 hours after rilpivirine. |
|
| Efavirenz Famotidine 430 | Green: Administer standard doses | Administer standard doses | No significant change |
40 mg x 1 dose | |||
| Raltegravir Famotidine 295 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC increased 45%; Cmax increased 60% |
20 mg daily given 2 hours before raltegravir | |||
| Elvitegravir Famotidine 134 | Green: Administer standard doses | Administer standard doses | No significant change in AUC or Cmax when administered 12 hours apart or if administered simultaneously |
40 mg given 12 hours after EVG or 40 mg given simultaneously with EVG | Not reported |
||
| Fostemsavir Famotidine 15 | Green: Administer standard doses | Administer standard doses | Temsavir Cmax increased 1%, AUC increased 4%, Cmin decreased 10% |
40mg single dose | Not reported |
